Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis

References

• NestleFOKaplanDHBarkerJPsoriasisN Engl J Med200936149650919641206
   PubMed Web of Science ®Google Scholar
• ParisiRSymmonsDPGriffithsCEAshcroftDMIdentification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project teamGlobal epidemiology of psoriasis: a systematic review of incidence and prevalenceJ Invest Dermatol201313337738523014338
   PubMed Web of Science ®Google Scholar
• ChandraARayASenapatiSChatterjeeRGenetic and epigenetic basis of psoriasis pathogenesisMol Immunol20156431332325594889
   PubMed Web of Science ®Google Scholar
• LowesMASuarez-FarinasMKruegerJGImmunology of psoriasisAnnu Rev Immunol20143222725524655295
   PubMed Web of Science ®Google Scholar
• DurhamLEKirkhamBWTaamsLSContribution of the IL-17 pathway to psoriasis and psoriatic arthritisCurr Rheumatol Rep2015175526209291
   PubMed Web of Science ®Google Scholar
• ArmstrongAWSchuppCWuJBeboBQuality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011PLoS One20127e5293523285231
   PubMed Web of Science ®Google Scholar
• LebwohlMGBachelezHBarkerJPatient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis SurveyJ Am Acad Dermatol20147087188124576585
   PubMed Web of Science ®Google Scholar
• OgdieAGelfandJMClinical risk factors for the development of psoriatic arthritis among patients with psoriasis: A review of available evidenceCurr Rheumatol Rep201517540
   Web of Science ®Google Scholar
• GisondiPTargherGZoppiniGGirolomoniGNon-alcoholic fatty liver disease in patients with chronic plaque psoriasisJ Hepatol20095175876419560226
   PubMed Web of Science ®Google Scholar
• GisondiPTessariGContiAPrevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control studyBr J Dermatol2007157687317553036
   PubMed Web of Science ®Google Scholar
• ArmstrongEJHarskampCTArmstrongAWPsoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studiesJ Am Heart Assoc20132e00006223557749
   PubMed Web of Science ®Google Scholar
• DavidoviciBSattarNPrinzJPsoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditionsJ Invest Dermatol20101301785179620445552
   PubMed Web of Science ®Google Scholar
• RobinsonAKardosMKimballABPhysician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasisJ Am Acad Dermatol20126636937522041254
   PubMed Web of Science ®Google Scholar
• FinlayAYPatient-reported outcome measures in psoriasis: assessing the assessmentsBr J Dermatol20151721178117925963202
   PubMed Web of Science ®Google Scholar
• PathiranaDOrmerodADSaiagPEuropean S3-guidelines on the systemic treatment of psoriasis vulgarisJ Eur Acad Dermatol Venereol200923Suppl 217019712190
   PubMed Web of Science ®Google Scholar
• Scottish Intercollegiate Guidelines Network (Scottish 2010)Diagnosis and management of psoriasis and psoriatic arthritis in adults Available from: http://sign.ac.uk/guidelines/fulltext/121/index.htmlAccessed May 11, 2016
   Google Scholar
• Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis2004 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdfAccessed May 11, 2016
   Google Scholar
• MrowietzUKragballeKReichKDefinition of treatment goals for moderate to severe psoriasis: a European consensusArch Dermatol Res201130311020857129
   PubMed Web of Science ®Google Scholar
• MrowietzUde JongEMKragballeKA consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasisJ Eur Acad Dermatol Venereol20142843845323437792
   PubMed Web of Science ®Google Scholar
• van de KerkhofPCAn update on topical therapies for mild-moderate psoriasisDermatol Clin201533737725412784
   PubMed Web of Science ®Google Scholar
• GisondiPTessariGDi MercurioMDel GiglioMGirolomoniGThe retention rate of systemic drugs in patients with chronic plaque psoriasisClin Dermatol20131814
   Google Scholar
• FinlayAYCurrent severe psoriasis and the rule of tensBr J Dermatol200515286186715888138
   PubMed Web of Science ®Google Scholar
• GisondiPCazzanigaSChimentiSMetabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare RegistryJ Eur Acad Dermatol Venereol201327e30e4122313340
   PubMed Web of Science ®Google Scholar
• GottliebABKalbRELangleyRGSafety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapiesJ Drugs Dermatol2014131441144825607786
   PubMed Web of Science ®Google Scholar
• KalbREFiorentinoDFLebwohlMGRisk of serious infection with biologic and systemic treatment of psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)JAMA Dermatol2015151996196925970800
   PubMed Web of Science ®Google Scholar
• ArmstrongAWRobertsonADWuJSchuppCLebwohlMGUndertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and 568 psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011JAMA Dermatol20131491180118523945732
   PubMed Web of Science ®Google Scholar
• BaumerWHoppmannJRundfeldtCKietzmannMHighly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasisInflamm Allergy Drug Targets20076172617352685
   PubMedGoogle Scholar
• SchaferPHPartonACaponeLApremilast is a selective PDE4 inhibitor with regulatory effects on innate immunityCell Signal2014262016202924882690
   PubMed Web of Science ®Google Scholar
• GottliebABMathesonRTMenterAEfficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label studyJ Drugs Dermatol20131288889723986162
   PubMed Web of Science ®Google Scholar
• PappKReichKLeonardiCLApremilast, an oral phosphodi-esterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (ESTEEM 1)J Am Acad Dermatol201573374926089047
   PubMed Web of Science ®Google Scholar
• PaulCCatherJGooderhamMEfficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)Br J Dermatol201517361387139926357944
   PubMed Web of Science ®Google Scholar
• FeldmanSThaciDLingMApremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: pruritus and DLQI correlations at week 16 (ESTEEM 1 and 2)J Am Acad Dermatol2015725 Suppl 1226
   Web of Science ®Google Scholar
• YosipovitchGPappKBagelJEffects of apremilast on pruritus in patients with moderate to severe plaque psoriasis: results from the ESTEEM 1 and 2 trialsPresented at: Annual Congress of the European Academy of Dermatology and VenereologyAmsterdam, The NetherlandsOctober 8–126382014
   Google Scholar
• CrowleyJGooderhamMWaselNApremilast, an oral phosphodiesterase 4 inhibitor, in patients with nail, scalp, and palmoplantar psoriasis 52-week results from the ESTEEM 2 trialPresented at: 73rd Annual Meeting of the American Academy of DermatologyMarch 20–24, 2015San Francisco, CA
   Google Scholar
• PappKReichKLeonardiCLApremilast, an oral phosphodi-esterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)J Am Acad Dermatol2015731374926089047
   PubMed Web of Science ®Google Scholar
• ReichKPappKGordonKLong-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis of two phase 3, randomized, controlled trials (ESTEEM 1 and 2)Presented at: Annual Congress of the European Academy of Dermatology and VenereologyOctober 8–12, 2014Amsterdam, The Netherlands
   Google Scholar
• ReichKSobellJStevensRDayRChange in weight with apremilast, an oral phosphodiesterase 4 inhibitor: pooled analysis of the ESTEEM 1 and ESTEEM 2 trialsPresented at: Annual Congress of the European Academy of Dermatology and VenereologyOctober 8–12, 2014Amsterdam, The Netherlands
   Google Scholar
• KragballeKvan de KerkhofPCGordonKBUnmet needs in the treatment of psoriasisEur J Dermatol20142452353225115238
   PubMed Web of Science ®Google Scholar
• MenterAPaulCStevensRMDayRMSahaKPsychiatric disorders and depression incidence with apremilast: pooled analysis of ESTEEM 1 and ESTEEM 2 trialsPresented at: the 23rd European Academy of Dermatology and VenereologyOctober 8–12, 2014Amsterdam, The Netherlands
   Google Scholar
• ThaçiDBlauveltAReichKSecukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialJ Am Acad Dermatol20157340040926092291
   PubMed Web of Science ®Google Scholar
• PappKReichKSobellJTwo years safety of apremilast in patients with moderate to severe psoriasis: results from randomised controlled trial ESTEEM 1Presented at: 73rd Annual Meeting of the American Academy of DermatologyMarch 20–24, 2015San Francisco, CA
   Google Scholar